Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Allogene Therapeutics (ALLO) Upgraded to Strong Buy: Here's What You Should Know
01:32pm, Friday, 10'th Nov 2023
Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Allogene Therapeutics, Inc. (ALLO) Q3 2023 Earnings Call Transcript
11:13pm, Thursday, 02'nd Nov 2023
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Christine Cassiano – Chief Corporate Affairs and Brand Strategy Officer D
Allogene Therapeutics Announces Participation in November Investor Conferences
08:30am, Monday, 30'th Oct 2023
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023
08:30am, Thursday, 26'th Oct 2023
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip
05:40am, Tuesday, 10'th Oct 2023
Caribou Biosciences stock could rocket up more than 400%, according to the consensus price target from Wall Street analysts. Caribou's lead candidate is an off-the-shelf cellular cancer therapy for ly
The Next Meme Stock: 6 Tickers Leading a Meme Stock Revival
07:01am, Friday, 18'th Aug 2023
Meme stocks are low-priced stocks that ran up in price for no particular fundamental reason other than short-squeezes perpetuated by retail investor enthusiasm and social media hype. The ridiculous na
Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss
12:45pm, Thursday, 03'rd Aug 2023
Allogene's (ALLO) second-quarter results beat estimates for earnings but misses the mark on sales. Management reiterated its previously-issued financial guidance for 2023.
Allogene Therapeutics, Inc. (ALLO) Q2 2023 Earnings Call Transcript
07:39pm, Wednesday, 02'nd Aug 2023
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President & C
Allogene Therapeutics (ALLO) Reports Q2 Loss, Misses Revenue Estimates
06:43pm, Wednesday, 02'nd Aug 2023
Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.52 per share a year ago.
Allogene: I Am Less Sanguine About Allogeneic CAR-T's Prospects Than Before
07:30pm, Wednesday, 26'th Jul 2023
Allogene Therapeutics, Inc. is the leading developer of allogeneic CAR-T. There was a time when its logic appealed to me. Lately, however, I have increasingly become disillusioned about its prospects.
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
08:30am, Wednesday, 26'th Jul 2023
SOUTH SAN FRANCISCO, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Wall Street Analysts See a 210.24% Upside in Allogene Therapeutics (ALLO): Can the Stock Really Move This High?
11:05am, Friday, 26'th May 2023
The mean of analysts' price targets for Allogene Therapeutics (ALLO) points to a 210.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
08:30am, Wednesday, 24'th May 2023
SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR
7 Short-Interest Stocks to Target for Explosive Gains
04:37pm, Thursday, 18'th May 2023
Ranking among the most speculative practices in the equities arena, deliberately bidding up short-interest stocks may generate wildly robust gains. At the same time, higher risks for the intrepid mark
PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up
12:47pm, Wednesday, 17'th May 2023
PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas.
